60 years ago, a small team of scientists, led by a visionary pharmacist, with limited financial resources, set the foundation for a modern and dynamic pharmaceutical company
ELPEN establishes its own production facilities, which transform the company into a leading player in the Greek pharmaceutical market. the company owns over 10,000 m2 facilities, which operate according to inetrnational GMP and ISO standards
The company wins its first major Tender and place its product in the private market with the aid of selected partners
is ELPEN's proprietary, patent protected, breath-activated, multi single-dose dry powder inhaler
ROLENIUM is ELPEN's fluticasone/salmeterol hybrid combination for the treatment of asthma & COPD, launched in Greece in Nov. 2009
ELPEN PHARMA GmbH subsidiary founded in Feb. 2012 in Berlin, Germany
ELPEN's International Business Division is created with the aim to consolidate its position as a preferred partner for the licensing and supply of Finished Dosage Forms
Expansion of ELPEN's activities in Consumer Health Care products
• New product development • Export activity enhancement
• Expansion of R&D and modernization of production facilities (Pikermi) • New production facility (Keratea) • Biotechnology Park - Athens LifeTech Park (Spata)
Launched in Europe
ELPEN Middle East Africa subsidiary founded in June 2024 in Dubai, UAE